» Articles » PMID: 22122642

Genome-wide DNA Methylation Profiling Using Infinium® Assay

Overview
Journal Epigenomics
Specialty Genetics
Date 2011 Nov 30
PMID 22122642
Citations 314
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Bisulfite sequence analysis of individual CpG sites within genomic DNA is a powerful approach for methylation analysis in the genome. The major limitation of bisulfite-based methods is parallelization. Both array and next-generation sequencing technology are capable of addressing this bottleneck. In this report, we describe the application of Infinium® genotyping technology to analyze bisulfite-converted DNA to simultaneously query the methylation state of over 27,000 CpG sites from promoters of consensus coding sequences (CCDS) genes.

Materials & Methods: We adapted the Infinium genotyping assay to readout an array of over 27,000 pairs of CpG methylation-specific query probes complementary to bisulfite-converted DNA. Two probes were designed to each CpG site: a 'methylated' and an 'unmethylated' query probe. The probe design assumed that all underlying CpG sites were 'in phase' with the queried CpG site due to their close proximity. Bisulfite conversion was performed with a modified version of the Zymo EZ DNA Methylation™ kit.

Results: We applied this technology to measuring methylation levels across a panel of 14 different human tissues, four Coriell cell lines and six cancer cell lines. We observed that CpG sites within CpG islands (CGIs) were largely unmethylated across all tissues (~80% sites unmethylated, β < 0.2), whereas CpG sites in non-CGIs were moderately to highly methylated (only ~12% sites unmethylated, β < 0.2). Within CGIs, only approximately 3-6% of the loci were highly methylated; in contrast, outside of CGIs approximately 25-40% of loci were highly methylated. Moreover, tissue-specific methylation (variation in methylation across tissues) was much more prevalent in non-CGIs than within CGIs.

Conclusion: Our results demonstrate a genome-wide scalable array-based methylation readout platform that is both highly reproducible and quantitative. In the near future, this platform should enable the analysis of hundreds of thousands to millions of CpG sites per sample.

Citing Articles

How epigenetics impacts stroke risk and outcomes through DNA methylation: A systematic review.

Gallego-Fabrega C, Cullell N, Fernandez-Cadenas I J Cereb Blood Flow Metab. 2025; :271678X251322032.

PMID: 40012472 PMC: 11866340. DOI: 10.1177/0271678X251322032.


DNA hypomethylation promotes UHRF1-and SUV39H1/H2-dependent crosstalk between H3K18ub and H3K9me3 to reinforce heterochromatin states.

Liu Y, Hrit J, Chomiak A, Stransky S, Hoffman J, Tiedemann R Mol Cell. 2024; 85(2):394-412.e12.

PMID: 39631394 PMC: 11741932. DOI: 10.1016/j.molcel.2024.11.009.


UHRF1 ubiquitin ligase activity supports the maintenance of low-density CpG methylation.

Tiedemann R, Hrit J, Du Q, Wiseman A, Eden H, Dickson B Nucleic Acids Res. 2024; 52(22):13733-13756.

PMID: 39607687 PMC: 11662662. DOI: 10.1093/nar/gkae1105.


Reduced Levels of miR-145-3p Drive Cell Cycle Progression in Advanced High-Grade Serous Ovarian Cancer.

Gonzalez-Canto E, Monteiro M, Aghababyan C, Ferrero-Mico A, Navarro-Serna S, Mellado-Lopez M Cells. 2024; 13(22).

PMID: 39594652 PMC: 11592657. DOI: 10.3390/cells13221904.


BS-clock, advancing epigenetic age prediction with high-resolution DNA methylation bisulfite sequencing data.

Hu C, Li Y, Li L, Zhang N, Zheng X Bioinformatics. 2024; 40(11).

PMID: 39499149 PMC: 11572488. DOI: 10.1093/bioinformatics/btae656.